文献速递妇科

生殖系BRCA突变携带者更可能因复发性铂敏感卵巢癌接受肿瘤细胞减灭术

Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-09-23

这项回顾性研究纳入1999年1月至2018年12月加拿大一个中心和以色列两个中心的147例铂敏感复发性高级别浆液性卵巢癌患者,按BRCA突变状态分组。31例(21.1%)接受了二次肿瘤细胞减灭术,生殖系BRCA突变携带者手术率为33.3%,无生殖系BRCA突变者为15.7%(p=0.026)。校正复发病灶数目后,其他变量均不再是显著预测因素。

要点

  • 生殖系BRCA突变携带者二次肿瘤细胞减灭术率为33.3%,无生殖系BRCA突变者为15.7%(p=0.026)。
  • 生殖系BRCA突变与二次肿瘤细胞减灭术相关(OR=2.5,p=0.03)。
  • 校正复发病灶数目后,其他变量均不再是显著预测因素。

核心结论

  • 生殖系BRCA突变携带者更可能接受二次肿瘤细胞减灭术,部分可能由复发时病灶体积较小介导。
  • 作者认为,在一线治疗后制定这些患者的监测计划时应考虑这一观察结果。

研究设计与样本

  • 回顾性研究,纳入1999年1月至2018年12月加拿大一个中心和以色列两个中心的铂敏感复发性高级别浆液性卵巢癌患者。
  • 共147例患者入组,其中加拿大97例、以色列50例;47例(32%)有BRCA突变,包括39例(26.5%)生殖系突变和8例(5.5%)体细胞突变。
  • 从电子病历获取人口学和遗传学数据、肿瘤特征、复发模式及手术和内科治疗信息,按BRCA突变状态分组。
  • 采用逻辑回归分析探索二次肿瘤细胞减灭术的潜在预后因素。

主要发现

  • 31例(21.1%)接受了二次肿瘤细胞减灭术。
  • 二次肿瘤细胞减灭术率在生殖系BRCA突变携带者为33.3%,在无生殖系BRCA突变者为15.7%(p=0.026)。
  • 二次肿瘤细胞减灭术的预测因素包括生殖系BRCA突变(OR=2.5,p=0.03)、复发时间(每延迟1个月OR=1.004,p<0.001)、无淋巴复发(OR=3.08,p=0.013)、复发时病灶三处或以下(OR=36.74,p<0.001)和无腹水(OR=9.1,p=0.034)。
  • 校正复发病灶数目后,其他变量均不再是显著预测因素。

临床怎么用

  • 作者认为,在一线治疗后为这些患者制定监测计划时应考虑生殖系BRCA突变携带者更可能接受二次肿瘤细胞减灭术这一观察结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: BRCA mutations have been associated with improved outcomes in ovarian cancer patients. This study's objective was to compare the secondary cytoreduction surgery (SCS) rates among ovarian cancer patients by BRCA mutation status. METHODS: The study was retrospective and included platinum sensitive recurrent high grade serous ovarian cancer patients from one Canadian center and two Israeli centers from January 1999 to December 2018. Demographic and genetic data, tumor characteristics, patterns of recurrence and surgical and medical treatments were obtained from electronic charts. Patients were grouped according to BRCA mutation status. Logistic regression analyses were used to explore potential prognostic factors of secondary cytoreduction. RESULTS: 147 patients were enrolled, including 97 from Canada and 50 from Israel. Forty-seven patients (32%) had a BRCA mutation, including 39 (26.5%) germline mutations and 8 (5.5%) somatic mutations. Thirty-one patients (21.1%) underwent SCS. The rate of SCS was 33.3% among the germline BRCA mutation carriers and 15.7% among patients without germline BRCA mutation (p = 0.026). Predictors of secondary cytoreduction included germline BRCA mutation (OR = 2.5, p = 0.03), time to recurrence (OR = 1.004 per month, p < 0.001), absence of lymphatic recurrence (OR = 3.08, p = 0.013), three or fewer lesions at recurrence (OR = 36.74, p < 0.001) and absence of ascites (OR = 9.1, p = 0.034). After adjusting for the number of lesions at recurrence, no other variable remained a significant predictor. CONCLUSION: Germline BRCA mutation carriers are more likely to undergo secondary cytoreduction. This may be mediated in part by lower volume disease at recurrence. This observation should be considered when planning surveillance for these patients after first-line treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yfat K, Mariam K, Mario B, et al. Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer. Gynecol Oncol. 2022. PMID: 36154762. doi:10.1016/j.ygyno.2022.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。